139 related articles for article (PubMed ID: 22345569)
1. Local serotonin mediates cyclic strain-induced phenotype transformation, matrix degradation, and glycosaminoglycan synthesis in cultured sheep mitral valves.
Lacerda CM; Kisiday J; Johnson B; Orton EC
Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H1983-90. PubMed ID: 22345569
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan hydroxylase 1 expression is increased in phenotype-altered canine and human degenerative myxomatous mitral valves.
Disatian S; Lacerda C; Orton EC
J Heart Valve Dis; 2010 Jan; 19(1):71-8. PubMed ID: 20329492
[TBL] [Abstract][Full Text] [Related]
3. Static and cyclic tensile strain induce myxomatous effector proteins and serotonin in canine mitral valves.
Lacerda CM; Maclea HB; Kisiday JD; Orton EC
J Vet Cardiol; 2012 Mar; 14(1):223-30. PubMed ID: 22364693
[TBL] [Abstract][Full Text] [Related]
4. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves.
Rabkin E; Aikawa M; Stone JR; Fukumoto Y; Libby P; Schoen FJ
Circulation; 2001 Nov; 104(21):2525-32. PubMed ID: 11714645
[TBL] [Abstract][Full Text] [Related]
5. Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease.
Disatian S; Orton EC
J Heart Valve Dis; 2009 Jan; 18(1):44-51. PubMed ID: 19301552
[TBL] [Abstract][Full Text] [Related]
6. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves.
Rabkin-Aikawa E; Farber M; Aikawa M; Schoen FJ
J Heart Valve Dis; 2004 Sep; 13(5):841-7. PubMed ID: 15473488
[TBL] [Abstract][Full Text] [Related]
7. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation.
Disatian S; Ehrhart EJ; Zimmerman S; Orton EC
J Heart Valve Dis; 2008 Jul; 17(4):402-11; discussion 412. PubMed ID: 18751470
[TBL] [Abstract][Full Text] [Related]
8. Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations.
Grande-Allen KJ; Griffin BP; Ratliff NB; Cosgrove DM; Vesely I
J Am Coll Cardiol; 2003 Jul; 42(2):271-7. PubMed ID: 12875763
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of Mitral Leaflet Matrix Composition and Turnover Correlates with Regional Leaflet Strain.
Stephens EH; Connell PS; Fahrenholtz MM; Timek TA; Daughters GT; Kuo JJ; Patton AM; Ingels NB; Miller DC; Grande-Allen KJ
Cardiovasc Eng Technol; 2015 Jun; 6(2):141-50. PubMed ID: 26213589
[TBL] [Abstract][Full Text] [Related]
10. Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.
Oyama MA; Elliott C; Loughran KA; Kossar AP; Castillero E; Levy RJ; Ferrari G
Cardiovasc Pathol; 2020; 46():107196. PubMed ID: 32006823
[TBL] [Abstract][Full Text] [Related]
11. The pathomechanism of human myxomatous valvular degeneration at the mechanical and cellular level.
Hu C; Wang Q; Xue H; Hong H; Shi J; Dong N; Zhang M
Rev Cardiovasc Med; 2021 Jun; 22(2):513-519. PubMed ID: 34258920
[TBL] [Abstract][Full Text] [Related]
12. Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data.
Hulin A; Deroanne C; Lambert C; Defraigne JO; Nusgens B; Radermecker M; Colige A
Cardiovasc Pathol; 2013; 22(4):245-50. PubMed ID: 23261354
[TBL] [Abstract][Full Text] [Related]
13. Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease.
Garcia-Pena A; Ibarrola J; Navarro A; Sadaba A; Tiraplegui C; Garaikoetxea M; Arrieta V; Matilla L; Fernández-Celis A; Sadaba R; Alvarez V; Gainza A; Jover E; López-Andrés N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669101
[TBL] [Abstract][Full Text] [Related]
14. Development and Evaluation of a Tissue-Engineered Fibrin-based Canine Mitral Valve Three-dimensional Cell Culture System.
Liu MM; Flanagan TC; Jockenhovel S; Black A; Lu CC; French AT; Argyle DJ; Corcoran BM
J Comp Pathol; 2018 Apr; 160():23-33. PubMed ID: 29729718
[TBL] [Abstract][Full Text] [Related]
15. Telotristat ethyl reverses myxomatous changes in mice mitral valves.
Wang X; Kuban-Johnston D; Lapuerta P; Lacerda CMR
Front Cardiovasc Med; 2022; 9():945672. PubMed ID: 35990981
[TBL] [Abstract][Full Text] [Related]
16. Developmental basis for filamin-A-associated myxomatous mitral valve disease.
Sauls K; de Vlaming A; Harris BS; Williams K; Wessels A; Levine RA; Slaugenhaupt SA; Goodwin RL; Pavone LM; Merot J; Schott JJ; Le Tourneau T; Dix T; Jesinkey S; Feng Y; Walsh C; Zhou B; Baldwin S; Markwald RR; Norris RA
Cardiovasc Res; 2012 Oct; 96(1):109-19. PubMed ID: 22843703
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration.
Tan K; Markby G; Muirhead R; Blake R; Bergeron L; Fici G; Summers K; Macrae V; Corcoran B
PLoS One; 2019; 14(8):e0221126. PubMed ID: 31415646
[TBL] [Abstract][Full Text] [Related]
18. Cellular and Extracellular Matrix Basis for Heterogeneity in Mitral Annular Contraction.
Stephens EH; Fahrenholtz MM; Connell PS; Timek TA; Daughters GT; Kuo JJ; Patton AM; Ingels NB; Miller DC; Grande-Allen KJ
Cardiovasc Eng Technol; 2015 Jun; 6(2):151-9. PubMed ID: 26195991
[TBL] [Abstract][Full Text] [Related]
19. Early Activation of Growth Pathways in Mitral Leaflets Exposed to Aortic Regurgitation: New Insights from an Animal Model.
Marsit O; Royer O; Drolet MC; Arsenault M; Couet J; Morin S; Levine RA; Pibarot P; Beaudoin J
J Heart Valve Dis; 2017 May; 26(3):281-289. PubMed ID: 29092112
[TBL] [Abstract][Full Text] [Related]
20. Structural and cellular changes in canine myxomatous mitral valve disease: an image analysis study.
Han RI; Black A; Culshaw G; French AT; Corcoran BM
J Heart Valve Dis; 2010 Jan; 19(1):60-70. PubMed ID: 20329491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
